Nuvalent, Inc.
NasdaqGS:NUVL Rapporto sulle azioni
Nuvalent Crescita futura
Future criteri di controllo 0/6 Nuvalent prevede che gli utili e i ricavi cresceranno rispettivamente di 3% e 65.5% all'anno. Si prevede che l'EPS diminuirà di 1.2% all'anno. Si prevede che il ritorno sul capitale proprio sarà di -28.9% in 3 anni.
Informazioni chiave
3.0%
Tasso di crescita degli utili
-1.2%
Tasso di crescita dell'EPS
Biotechs crescita degli utili 27.3% Tasso di crescita dei ricavi 65.5% Rendimento futuro del capitale proprio -28.9% Copertura analitica Good
Ultimo aggiornamento 12 Nov 2024
Aggiornamenti recenti sulla crescita futura
Price target increased by 8.1% to US$111 Sep 16
Price target increased by 10% to US$102 Apr 01
Price target increased by 8.6% to US$92.13 Feb 28
Price target increased by 7.4% to US$84.83 Feb 12
Price target increased by 11% to US$59.14 Oct 05
Price target increased by 8.7% to US$50.83 Aug 10
Mostra tutti gli aggiornamenti
CFO & Treasurer exercised options and sold US$613k worth of stock Nov 05
CEO, President & Director notifies of intention to sell stock Oct 17
CFO & Treasurer notifies of intention to sell stock Oct 02
Nuvalent: Promising Data Keeps Validating Pipeline And Platform Sep 23 Nuvalent, Inc. has completed a Follow-on Equity Offering in the amount of $500 million. Sep 18
Nuvalent: Likely Approvals Coming Up Do Not Justify This Valuation Sep 17 Nuvalent, Inc. has completed a Follow-on Equity Offering in the amount of $500 million.
Price target increased by 8.1% to US$111 Sep 16 Nuvalent, Inc. has filed a Follow-on Equity Offering in the amount of $350 million. Sep 16
Nuvalent, Inc. Announces Publication in Cancer Discovery Detailing Design and Characterization of Alk-Selective Inhibitor Nvl-655 Sep 13
CFO & Treasurer exercised options and sold US$564k worth of stock Sep 05
New major risk - Revenue and earnings growth Aug 11
Nuvalent (NASDAQ:NUVL) Is In A Strong Position To Grow Its Business Aug 05
CFO & Treasurer exercised options and sold US$517k worth of stock Aug 04
Nuvalent, Inc. Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor Jul 22
Nuvalent, Inc. Announces Promotion of Henry Pelish to Chief Scientific Officer Jul 11
CFO & Treasurer notifies of intention to sell stock Jun 30
Nuvalent: Making Precise Progress In Its Oncology Pipeline Jun 24
Independent Director notifies of intention to sell stock Jun 17
Nuvalent: NVL-655 Could Bring Blockbuster Potential Jun 14
Chief Legal Officer & Secretary exercised options and sold US$528k worth of stock Jun 10
Nuvalent, Inc. Receives U.S. FDA Breakthrough Therapy Designation for NVL-655 May 18
Nuvalent, Inc., Annual General Meeting, Jun 12, 2024 Apr 28
Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation Apr 22
Price target increased by 10% to US$102 Apr 01
Independent Director notifies of intention to sell stock Mar 18
Price target increased by 8.6% to US$92.13 Feb 28
Nuvalent: Pivotal NSCLC Programs Progressing With Additional Data In 2024 Feb 26
Price target increased by 7.4% to US$84.83 Feb 12
Nuvalent, Inc. Initiates the Phase 2 Portion of Alkove-1 Clinical Trial for Patients with Alk-Positive Nsclc and Other Solid Tumors Feb 12
Is Nuvalent, Inc. (NASDAQ:NUVL) Trading At A 36% Discount? Jan 07
Chief Development Officer notifies of intention to sell stock Dec 20
Founder notifies of intention to sell stock Oct 27
Chief Development Officer notifies of intention to sell stock Oct 06
New minor risk - Share price stability Oct 05
Price target increased by 11% to US$59.14 Oct 05
Companies Like Nuvalent (NASDAQ:NUVL) Can Afford To Invest In Growth Sep 23
Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium Sep 19
Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with Ros1-Positive NSCLC and Other Solid Tumors Sep 06
New major risk - Revenue and earnings growth Aug 11
Price target increased by 8.7% to US$50.83 Aug 10
Chief Legal Officer & Secretary notifies of intention to sell stock Jul 30
Price target increased by 8.7% to US$50.80 Jul 24
Chief Legal Officer & Secretary notifies of intention to sell stock Jul 19
Chief Development Officer notifies of intention to sell stock Jun 19
Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation Jun 10
Chief Development Officer exercised options and sold US$125k worth of stock Jun 04
Price target increased by 10% to US$46.75 May 18
Chief Development Officer exercised options and sold US$113k worth of stock May 04
Chief Development Officer exercised options and sold US$77k worth of stock Apr 06
Chief Development Officer exercised options and sold US$86k worth of stock Mar 05
We're Interested To See How Nuvalent (NASDAQ:NUVL) Uses Its Cash Hoard To Grow Feb 24
Chief Legal Officer & Secretary notifies of intention to sell stock Feb 20
Chief Development Officer exercised options and sold US$85k worth of stock Feb 05
Chief Legal Officer & Secretary exercised options and sold US$51k worth of stock Jan 20
Chief Development Officer exercised options and sold US$121k worth of stock Dec 18
Nuvalent Inc. Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-selective inhibitor NVL-520 Dec 14
Chief Development Officer exercised options and sold US$130k worth of stock Nov 18
Price target increased to US$43.67 Nov 16
High number of new directors Nov 16
Chief Legal Officer & Secretary exercised options and sold US$287k worth of stock Nov 03
Nuvalent, Inc. Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial that Support Best-In-Class Potential of NVL-520 for Patients withROS1-Positive NSCLC Oct 28
Chief Development Officer exercised options and sold US$85k worth of stock Oct 15 Nuvalent, Inc. Currently Enrolling Patients in the Phase 1 Portion of Its Arros-1 Study, A Phase 1/2 Clinical Trial
Chief Development Officer exercised options and sold US$72k worth of stock Sep 17
Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation Sep 13
Nuvalent, Inc. Present Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 at 34th EORTC-NCI-AACR Symposium and Announces Pipeline Updates Sep 08
Nuvalent GAAP EPS of -$0.38 beats by $0.03 Aug 10
Nuvalent, Inc. Presents New Preclinical Data Supporting Potential Best-In-Class Profile for ALK-Selective Inhibitor NV-655 At IASLC 2022 World Conference on Lung Cancer Annual Meeting Aug 06
Nuvalent, Inc. Announces Leadership Promotions Jul 21
Insider exercised options and sold US$278k worth of stock Jul 09 Nuvalent, Inc.(NasdaqGS:NUVL) dropped from Russell 2000 Growth Index
Nuvalent, Inc. Announces Clinical Progress on Parallel Lead Programs NVL-520 and NVL-655 for NSCLC and Solid Tumor Cancers Jun 22
Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation May 28
Now 21% undervalued after recent price drop May 24
Chief Medical Officer exercised options to buy US$117k worth of stock. May 20
Now 25% undervalued after recent price drop May 09
Nuvalent, Inc., Annual General Meeting, Jun 16, 2022 May 02
High number of new directors Apr 27
High number of new directors Apr 07
Nuvalent, Inc. Appoints Anna Protopapas as Chair of Board of Directors Apr 01 Nuvalent to Present New Preclinical Data on ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2022 Mar 10
Insider exercised options and sold US$68k worth of stock Feb 18
Nuvalent Appoints Emily Drabant Conley to Board of Directors Feb 04
Nuvalent, Inc Announces First Patient Dosed in ARROS-1 Phase 1/2 Clinical Trial of NVL-520, its Novel ROS1-selective Inhibitor Jan 09
We're Hopeful That Nuvalent (NASDAQ:NUVL) Will Use Its Cash Wisely Oct 29
Previsioni di crescita degli utili e dei ricavi NasdaqGS:NUVL - Stime future degli analisti e dati finanziari passati (USD Millions ) Data Ricavi Guadagni Flusso di cassa libero Liquidità dell'operazione Avg. Numero di analisti 12/31/2026 34 -319 -227 -351 10 12/31/2025 N/A -282 -213 -245 10 12/31/2024 N/A -231 -207 -156 10 6/30/2024 N/A -174 -130 -130 N/A 3/31/2024 N/A -146 -111 -111 N/A 12/31/2023 N/A -126 -100 -100 N/A 9/30/2023 N/A -114 -87 -87 N/A 6/30/2023 N/A -100 -83 -83 N/A 3/31/2023 N/A -89 -76 -76 N/A 12/31/2022 N/A -82 -65 -65 N/A 9/30/2022 N/A -73 -60 -60 N/A 6/30/2022 N/A -66 -53 -53 N/A 3/31/2022 N/A -57 -48 -48 N/A 12/31/2021 N/A -46 -40 -40 N/A 9/30/2021 N/A -36 -32 -32 N/A 6/30/2021 N/A -28 -25 -25 N/A 3/31/2021 N/A -27 -18 -18 N/A 12/31/2020 N/A -15 -15 -15 N/A
Mostra di più
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Si prevede che NUVL rimarrà non redditizia nei prossimi 3 anni.
Guadagni vs Mercato: Si prevede che NUVL rimarrà non redditizia nei prossimi 3 anni.
Guadagni ad alta crescita: Si prevede che NUVL rimarrà non redditizia nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che NUVL non avrà alcun fatturato il prossimo anno.
Ricavi ad alta crescita: Si prevede che NUVL non avrà alcun fatturato il prossimo anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Si prevede che NUVL non sarà più redditizia tra 3 anni.
Scoprire le aziende in crescita Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
